Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study

Magazine, Rahul and Shahul, Hameed Aboobackar and Chogtu, Bharti and Kamath, Asha (2016) Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study. Lung India, 33 (3). pp. 281-286. ISSN 0970-2113

[img] PDF
2016_Lung India_Zileuton.pdf - Published Version
Restricted to Registered users only

Download (693kB) | Request a copy

Abstract

Background: Leukotriene modifiers have an established role in the management of chronic asthma but their role in acute asthma is still under evaluation. Objective: To study and compare the effects of oral montelukast with oral zileuton in acute asthma. Materials and Methods: This study included 120 asthmatics and was conducted from September 2012 to March 2014. Patients were randomized into three different groups to receive montelukast or zileuton or placebo in addition to standard treatment for asthma exacerbation. Peak expiratory flow rate (PEFR) values, details of rescue medication and vital signs were recorded at 6 h, 12 h, 24 h, and 48 h of drug or placebo administration and at discharge. Additional recording was done in the morning (8-10 am) following admission. The primary endpoint was the mean PEFR of each group at these time points; the secondary end point being the need for rescue medications. Results: The mean PEFR recordings of the three study groups - placebo, montelukast, and zileuton - respectively, at various time points were as follows: at 6 h (223.25 ± 90.40, 199.00 ± 82.52, 233.75 ± 84.05; P = 0.240); at 12 h (271.00 ± 109.38, 251.50 ± 101.44, 309.50 ± 129.63; P = 0.048); at 24 h (288.25 ± 114.26, 269.00 ± 107.51, 324.50 ± 127.88; P = 0.080); and at 48 h (295.00 ± 114.80, 293.50 ± 113.24, 344.75 ± 119.91; P = 0.015); discharge (305.00 ± 118.56, 305.25 ± 119.51, 361.25 ± 119.70; P = 0.010). The mean PEFR for the three study groups at 8-10 am on the morning following admission was 268.75 ± 111.43, 252.50 ± 99.99, 306.75 ± 114.44; P = 0.047. Total rescue doses needed were 10, 1, and 0, respectively (P = 0.049). Conclusion: Zileuton is better than montelukast as an additional drug in acute asthma and results in significant improvement in lung function, and reduction in the need for rescue medications.

Item Type: Article
Uncontrolled Keywords: Acute asthma ; montelukast; zileuton.
Subjects: Medicine > KMC Manipal > Community Medicine
Medicine > KMC Manipal > Pharmacology
Medicine > KMC Manipal > Pulmonary Medicine
Depositing User: KMC Library
Date Deposited: 25 Apr 2016 11:07
Last Modified: 25 Apr 2016 11:07
URI: http://eprints.manipal.edu/id/eprint/145919

Actions (login required)

View Item View Item